Clinical Trial Search

Primary: Change From Baseline in Weekly Average WI-NRS at Week 8 — -4.3; -1.1; -4.3; -3.7 score on a scale — p=0.3980

Primary: Change From Baseline in Fugl-Meyer Motor Scale (FMMS) Score at Week 24 Among All Patients — 6.0; 11.0; 8.1; 2.3 Change in score on a scale from baseline — p=0.0401

Primary: Number of Participants With at Least One Grade 2 (Moderate) or Higher Treatment-emergent Adverse Event — 1; 0; 0; 1 Participants

Primary: Part 1: Dose-limiting Toxicity (DLT) — 1; 0 Participants

Primary: Evaluate Efficacy & Safety of HP-5000 Topical Patches in Subjects With Osteoarthritis of the Knee: Change in Osteoarthritis Pain Score — -6.3; -5.6; -5.2 score on a…

Primary: Progression-free Survival (PFS) Based on Central Independent Review — 3.65; 4.17 months — p=0.2744

Primary: Proportion of Subjects With BCVA Gain of 15 or More Letters From Baseline in the Study Eye — 1; 1; 1 Participants

Primary: Change in Blood Absolute Eosinophil Count From Baseline to Week 12 — 0.8980; 0.4031; 0.3056; 0.2051 ratio to baseline — p=<.0001

Primary: Change From Baseline in Pulmonary Vascular Resistance — -52.2 dynes.sec/cm5

Primary: Number of Subjects Achieving Response to Therapy, Defined as Reduction in the CDAI Score and in Inflammatory Markers CRP or FCP at Day 42. — 29; 16 Participants

Primary: Progression at 6 Months — 11; 7 Participants

Primary: Change From Baseline in Muscle Tissue PGC1alpha (AU) at 8 Weeks — 0.55; 0.86 AU — p=0.0434

Primary: Number of Participants Experiencing ≥1 Adverse Events (AEs) — 56; 13 Participants

Primary: Maximum Tolerated Dose (MTD) — 300 mg

Primary: Pharmacokinetics Outcome: Absolute Values of (+)-Epicatechin Serum Concentration, Pre-dose (Trough) and 2 Hours Post-dose (Peak) — 15.1; 33.9; 20.6; 481.2 nM — p=0.0482